Background Vesnarinone Trial (VesT) was a three-armed, placebo-controlled, randomized clinical trial designed to study the effects of 30 mg or 60 mg/day vesnarinone. Certain contradictory results involving patient health-related quality-of-life (HRQOL) and overall survival (OS) have made a definitive and unified conclusion difficult. Methods To reconcile these findings, we have focused on the HRQOL-adjusted OS, commonly known as qualityadjusted life years (QALYs). Currently, analyses of QALYs incorporate a single HRQOL subscale. However, the VesT HRQOL instrument had two subscales: physical (PHYS) and emotional (EMOT). We have developed new ways to visualize and compare EMOT-and PHYS-adjusted OS. Results In each VesT arm, there was an increased probability of superior EMOT-adjusted OS, compared to PHYS-adjusted OS. The magnitude of these findings was comparable across trial arms. Despite inferior survival and superior EMOT and PHYS scores, the 60-mg/day arm presents similar EMOT-and PHYS-adjusted OS compared to the placebo arm. Conclusions We have provided a fresh perspective on the complex interactions between multiple HRQOL dimensions and OS. These novel methods address the burgeoning need for robust information on the interplay between OS and HRQOL from a patient, clinical care and public policy perspective.
Introduction
Time-to-event (TTE) endpoints, such as overall survival (OS) or disease-free survival, are commonly assessed in clinical research. Often, health-related quality of life (HRQOL) is collected as a secondary endpoint of interest, as HRQOL outcomes have become more relevant in clinical trials [1] . A strong dual relationship exists between the clinical and HRQOL aspects of patient health. The TTE influences certain HRQOL dimensions, such as physical/ social functioning, energy/vitality or bodily pain [2] . On the other hand, HRQOL history may be associated with extended or shortened TTE durations. Accounting for these synergistic dimensions provides additional insight into the subtle quality/quantity-of-life interplay that separate HRQOL and TTE analyses would not otherwise reveal.
Current methods for combining TTE and HRQOL often utilize overall HRQOL or a single HRQOL dimension (i.e., subscale) at a time [3, 4] . However, patient health status is too complex to only be summarized using the overall HRQOL or a single subscale. Whenever possible, information from multiple HRQOL subscales should be incorporated into HRQOL-adjusted TTE analyses [5, 6] . The Vesnarinone Trial (VesT) [7] was a three-arm, double-blind, placebocontrolled randomized clinical trial for patients with severe heart failure. In VesT, patients were randomized to 30 mg of vesnarinone, 60 mg of vesnarinone, or placebo. HRQOL data were collected at baseline, 8, 16 and 26 months thereafter, using the Minnesota Living with Heart Failure (MLHF) questionnaire [8] that has two subscales: emotional (EMOT) and physical (PHYS). Each VesT participant may value/perceive potential trial benefits differently. Some may value long-term improvements on the physical subscale, while experiencing short-time decreases in the emotional subscale. Others may prefer less emotional distress, at the expense of slight reductions in physical function.
Therefore, we sought to answer the following questions:
(1) How does one visualize the interplay between EMOT-adjusted and PHYS-adjusted OS in each trial arm? (2) Within each trial arm, is there a greater benefit in the EMOT-adjusted OS than in the PHYS-adjusted OS during follow-up? (3) If so, is this benefit manifested differentially among the trial arms?
To address these questions, we propose new visual and analytical methods to depict and quantify any trade-offs between HRQOL-adjusted OS on various subscales, such as the EMOT and PHYS subscales in the VesT example.
Multiply HRQOL-adjusted TTE and a trade-off measure
The HRQOL-adjusted-life-year (QALY) method is a simple and easily interpretable summarizing measure [9] . Patient health is classified into a number of health states, each having a utility value. QALY represents the sum of the utility-weighted time periods spent in each health state. Sensitivity analyses of the utility weights in QALY have been described in the literature [10] [11] [12] [13] . If T represents the overall survival (OS) time, define Q (1) T and Q (2) T to be the EMOT-and PHYS-adjusted OS in the VesT, respectively. To address our first question, we propose a simple trade-off measure TOF(t) = P(
, where t C 0. TOF describes how gains in HRQOL-adjusted OS on the EMOT and PHYS scales compare. Positive TOF values demonstrate that EMOTadjusted OS is greater than PHYS-adjusted OS at time t. Confidence intervals for TOF(t) are described in the ''Appendix''.
To address the second and third questions, we developed a method to compare TOF(t) values in two independent groups. Let TOF group 1 (t) and TOF group 2 (t) be the TOF(t) values in groups 1 and 2, respectively. Confidence intervals for the difference TOF group 1 (t) -TOF group
The Vesnarinone Trial (VesT) example Following a 2-week stabilization period, VesT participants were randomized with equal probability. A total of 3,833 patients with left ventricular ejection fraction of 30 % or less were enrolled between 01/95 and 07/96. The trial was stopped on July 31, 1996, when the prespecified total number of deaths had been reached in the placebo arm. The mean follow-up time was 286 days. Patient baseline characteristics shown in Table 1 were similar across trial arms.
HRQOL was assessed using the Minnesota Living with Heart Failure (MLHF) questionnaire, which has two subscales: physical (PHYS) (range from 0 to 40 in 5-unit increments) and emotional (EMOT) (range 0-25 in 5-unit increments). On each subscale, high values mean low HRQOL. To facilitate analysis, PHYS and EMOT have been transformed to a 0-100 scale: 2.5 9 (40 -PHYS) for PHYS and 4 9 (25 -EMOT) for EMOT. For the new scores, higher values mean better HRQOL. Only patients with baseline PHYS and EMOT scores were analyzed (1,167 in the placebo arm, 1,154 in the 30 mg/day arm and 1,162 in the 60 mg/day arm).
Mean PHYS and EMOT values and corresponding 95 % pointwise confidence intervals at randomization, 8, 16 and 26 weeks post-baseline are shown in Fig. 2 . At 8 weeks post-baseline, the 60-mg/day arm participants had significantly higher mean PHYS (p = 0.016) and EMOT (p = 0.001) scores compared to the placebo arm participants. Similar results were observed at 16 weeks (p = 0.007 and 0.006, respectively). However, as revealed by the log-rank (LR) test, all-cause mortality at 8 and 16 weeks was higher in the 60-mg/day arm than in the placebo arm (LR = 5.80, degrees of freedom = 1, p value = 0.02, Cohn et al. [7] ) (Fig. 1) . Attempting to reconcile these contradictory results, we have focused on the trade-off functions TOF instead. Let T be the OS (in weeks since randomization). Let Q (1) T and Q (2) T be the PHYS-and the EMOT-adjusted versions of T, respectively. Let the trade-off function be TOF(t) = P(
, where Q(s) = s/100, for s ¼ 0; 1. . .; 100. In each VesT arm, TOF(t) was estimated at t = 0, 7, 14, 21, 28 and 35 weeks post-baseline and is shown in Fig. 3 .
Within-group TOF evaluation
To address our second question, note in each arm, there is a trend favoring greater EMOT-adjusted compared to PHYSadjusted OS (Fig. 3) . In the placebo arm, the TOF (standard error SE) gain was 0. 
Between-groups TOF comparisons
To address the third question, the three trial arms were compared in pairwise fashion in terms of trade-off functions TOF(t) at weeks t = 0, 7, 14, 21, 28 and 35. Results are displayed in Fig. 4 . When comparing the placebo and the 30-mg/day arms ( Fig. 4a) , we found virtually no differences in TOF patterns over time, with the exception of week 21, when the TOF was borderline significantly larger in the placebo arm: TOF = 0.08 (0.04), p = 0.049. A similar result was seen when comparing the placebo and 60-mg/day arms, with TOF reaching significance at week 21 only: TOF = 0.09 (0.04), p = 0.036. However, the Currently, analyses of HRQOL-adjusted survival times typically involve the overall HRQOL score or a single HRQOL subscale. However, HRQOL data collection instruments such as the EQ-5D [3, 4, 14] , the SF-12 [15] or the SF-36 [16] include multiple relevant HRQOL dimensions. They provide important information that would otherwise not be gleaned from use of overall HRQOL in the determination of QALYs. We propose new graphical methods and a trade-off function to describe the complex relationship between multiple HRQOL scales and time to event. This approach facilitates comparisons of trade-off functions, both within and between groups.
Robustness of conclusions in QALY studies is typically assessed using sensitivity analyses [17, 18] . Using derivations similar to those in the ''Appendix,'' the methodology developed can be extended to study the role of the utility functions. Then, comparisons of QALY gains on the PHYS and/or EMOT dimensions can be related to the utility function specification. As a result, more robust conclusions will be obtained. This research will be disseminated in a separate report.
When more than two HRQOL dimensions are available, the trade-off function TOF is replaced by a multidimensional surface. Smoothing techniques can be used to create a more regular TOF surface and to facilitate visual assessment. The mathematical derivations necessary to extend the present results to the context of more than two HRQOL subscales are relatively straightforward.
In the VesT example, these methods indicate that the EMOT-adjusted OS tends to be favored, in comparison with PHYS-adjusted OS, in each trial arm. This demonstrates the complexity of HRQOL and the value of studying not just overall HRQOL, but also dimensions of HRQOL as they relate to survival. Furthermore, despite inferior survival and superior EMOT and PHYS scores, the 60-mg/day arm presents similar EMOT-and PHYS-adjusted OS compared to the placebo arm. This finding provides important information on the relative value of treatment (i.e., 60 mg of vesnarinone) versus no treatment from the perspective of HRQOL.
As HRQOL data are collected in numerous studies [19, 20] , we anticipate that the methods developed here will help provide a fresh perspective on the complex interactions between patient health and survival. Although our example is from a heart failure trial, these methods can be applied to a wide range of disease-specific studies, including both acute and chronic diseases and the study of specific cohorts within populations of patients. Ultimately, these novel methods contribute to the burgeoning need for robust information on the interplay between survival and HRQOL from a patient, clinical care and public policy perspective.
Commonly Since T is adjusted on two different HRQOL scales, the resulting Q (1) T and Q (2) T are correlated. Their joint distribution is necessary to perform testing for significance.
Assume the existence of a constant 
The expression in (1) is a sum of zero-mean i.i.d. terms, so it converges to zero in probability. In addition, (2) is bounded from above, in absolute value, by supfj b
so it converges to zero, in probability. This shows that b H 1;2 ðÁ; ÁÞ is a consistent estimator of H 1;2 ðÁ; ÁÞ; hence, an estimator for F 1;2 ðÁ; ÁÞ can be derived easily. [23] , it follows that for all t maxf e T j ; j ¼ 1; . . .; ng, we have that
Limiting distribution results

Let
GðuÀÞ GðuÞ P n j¼1 dM j c ðuÞ P n j¼1 Ið e T j ! uÞ : 
it follows that the second term in (3) can be written as using arguments as in [24] . Standard results for stochastic integrals with respect to martingales lead to the fact that the expression in (6) 
Confidence intervals
Based on these derivations, a 100 9 (1 -a)-level confidence interval for TOF(t) is ½ d TOFðtÞÀ z 1Àa ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi b r H 1;2 ðt; 0; 0; tÞ=n p ; d TOFðtÞþ z 1Àa ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi b r H 1;2 ðt; 0; 0; tÞ=n p , where n is the group size and z 1-a is the upper a th quantile of the N(0, 1) distribution. We now focus on the two-group setting. Let n 1 and n 2 be the sample sizes of the two groups, respectively. A 100 9 (1 -a) 
